URB597


Selective FAAH inhibitor (research)

A carbamate inhibitor of fatty acid amide hydrolase (FAAH); the canonical research probe for elevating endogenous anandamide.

Abstract

URB597 (KDS-4103, cyclohexyl carbamic acid 3′-carbamoyl-biphenyl-3-yl ester; CAS 546141-08-6; molecular formula C20H22N2O3; molecular weight 338.40) is a covalent carbamate inhibitor of fatty acid amide hydrolase (FAAH) developed by Piomelli and colleagues at UC Irvine. The compound carbamoylates the active-site serine of FAAH, producing irreversible enzyme inactivation. Selective for FAAH over MAGL and other lipases. Pharmacological consequence: elevation of endogenous anandamide and other N-acylethanolamides without direct CB receptor agonism. The behavioral profile differs from direct CB1 agonists like THC: anxiolytic and analgesic effects without the catalepsy, hypothermia, and intoxication characteristic of CB1 full agonism. Phase 2 clinical trials in major depressive disorder did not demonstrate efficacy; the compound did not advance to phase 3. Used as the canonical FAAH inhibitor in academic neuroscience.

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.


Browse all monographs

Previous monograph
Next monograph